New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
February 13, 2019 - Novartis announced the FDA approval of Egaten (triclabendazole), for the treatment of fascioliasis in patients 6 years of age and older.
Download PDF
Return to publications
